Comparative Pharmacology
Head-to-head clinical analysis: CARBIDOPA versus DUOPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBIDOPA versus DUOPA.
CARBIDOPA vs DUOPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbidopa inhibits peripheral decarboxylation of levodopa, increasing levodopa availability to the brain.
DUOPA is a combination of carbidopa and levodopa. Levodopa is a precursor of dopamine that crosses the blood-brain barrier and is converted to dopamine in the brain, replenishing depleted dopamine stores in the striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing the availability of levodopa for transport to the brain.
Oral, 25 mg carbidopa with 100 mg levodopa (Sinemet 25/100) three times daily, titrated based on response. Maximum 200 mg carbidopa per day.
One capsule orally, once daily at bedtime. Dose strengths available: 23.75 mg/9.5 mg (carbidopa/levodopa), 36.25 mg/14.5 mg, 48.75 mg/19.5 mg, 61.25 mg/24.5 mg. Titrate based on efficacy and tolerability; maximum dose 61.25 mg/24.5 mg.
None Documented
None Documented
Clinical Note
moderateCarbidopa + Droxidopa
"The therapeutic efficacy of Droxidopa can be decreased when used in combination with Carbidopa."
1-2 hours (terminal); clinically, coadministration with carbidopa does not alter levodopa half-life but reduces peripheral metabolism.
Levodopa 1-2 h; carbidopa 1-2 h; clinical context: short t1/2 requires frequent dosing; extended-release formulation prolongs
Renal: 70% as metabolites, 30% unchanged; biliary/fecal: minimal (<5%).
Renal: carbidopa ~50% unchanged, levodopa minimal; fecal: ~30% of levodopa metabolites; biliary: minor
Category A/B
Category C
Decarboxylase Inhibitor
Decarboxylase Inhibitor/Dopamine Precursor Combination